Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer

Douglas A. Schow, Leonard G. Renfer, Thomas A. Rozanski, Ian M. Thompson

Research output: Contribution to journalArticle

63 Scopus citations


Objectives. We sought to determine the prevalence of hot flushes after neoadjuvant hormonal therapy. Methods. Forty-three patients who received neoadjuvant hormonal therapy before radical prostatectomy were asked to complete a questionnaire regarding hot flushes. Results. Complete information was available for 35 of the 43 patients. No hot flushes were noted in 20%; in 69%, hot flushes were noted during treatment but resolved after termination of treatment; and in 11%, hot flushes continued for at least 3 months after cessation of hormonal therapy. Analyzing the data with respect to duration of hormonal therapy showed that patients receiving neoadjuvant hormonal therapy for more than 4 months had the highest incidence of persistent hot flushes. Conclusions. Hot flushes will be noted in 80% of patients who receive neoadjuvant hormonal therapy. In approximately 10%, hot flushes will continue for a significant period after hormonal therapy is terminated. Patients should be apprised of this potential side effect.

Original languageEnglish (US)
Pages (from-to)855-857
Number of pages3
JournalSouthern medical journal
Issue number9
StatePublished - Sep 1998


ASJC Scopus subject areas

  • Medicine(all)

Cite this